OBJECTIVE: The objective of our study was to investigate secretin-stimulated MRCP in terms of the safety of secretin, improvement of duct visualization, and assessment of pancreatic exocrine function. MATERIALS AND METHODS: Eight hundred sixteen volunteers (370 women and 446 men; mean age, 49.7 ± 13.1 [SD] years) underwent 3D MRCP before and after secretin stimulation (1 U/kg of body weight) at 1.5 T. For the first 2 hours after secretin injection, subjects were evaluated for adverse reactions. Improvement of duct visualization after secretin stimulation was subjectively evaluated by two readers and was quantified by duct diameter measurements. Pancreatic exocrine function was evaluated subjectively by two readers according to the duodenal filling and was quantified using calibrated volumetric measurements of total excreted volume and pancreatic flow output. RESULTS: Two subjects (0.2%) showed flushing (minor adverse reaction). Duct visualization after secretin injection was improved for reader 1 in 468 (57.4%) and for reader 2 in 478 (58.6%) subjects, was unchanged for reader 1 in 324 (39.7%) and for reader 2 in 315 (38.6%) subjects, and was worse for reader 1 in 24 (2.9%) and reader 2 in 23 (2.8%) subjects (interrater agreement, κ = 0.925). Main pancreatic duct diameters increased significantly after secretin stimulation: pancreatic head, 10.5% (mean); body, 12.5%; and tail, 7.7%. Pancreatic exocrine function evaluated according to assessment of duodenal filling was as follows: grade 0 (restricted function) in 0.7% of subjects by both readers, grade 1 (reduced function) in 4.8% of subjects by reader 1 and 4.5% of subjects by reader 2, grade 2 (low-grade reduced function) in 31.1% of subjects by reader 1 and 26.5% of subjects by reader 2, and grade 3 (physiologic function) in 63.4% of subjects by reader 1 and 68.3% of subjects by reader 2 (interrater agreement, κ = 0.838). The mean total excreted volume was 111.8 ± 49.8 (SD) mL, and the mean pancreatic flow output was 9.6 ± 4.2 mL/min. CONCLUSION: Secretin-stimulated MRCP moderately improves main pancreatic duct visualization and allows noninvasive quantification of pancreatic exocrine function with a negligible risk of side effects.
OBJECTIVE: The objective of our study was to investigate secretin-stimulated MRCP in terms of the safety of secretin, improvement of duct visualization, and assessment of pancreatic exocrine function. MATERIALS AND METHODS: Eight hundred sixteen volunteers (370 women and 446 men; mean age, 49.7 ± 13.1 [SD] years) underwent 3D MRCP before and after secretin stimulation (1 U/kg of body weight) at 1.5 T. For the first 2 hours after secretin injection, subjects were evaluated for adverse reactions. Improvement of duct visualization after secretin stimulation was subjectively evaluated by two readers and was quantified by duct diameter measurements. Pancreatic exocrine function was evaluated subjectively by two readers according to the duodenal filling and was quantified using calibrated volumetric measurements of total excreted volume and pancreatic flow output. RESULTS: Two subjects (0.2%) showed flushing (minor adverse reaction). Duct visualization after secretin injection was improved for reader 1 in 468 (57.4%) and for reader 2 in 478 (58.6%) subjects, was unchanged for reader 1 in 324 (39.7%) and for reader 2 in 315 (38.6%) subjects, and was worse for reader 1 in 24 (2.9%) and reader 2 in 23 (2.8%) subjects (interrater agreement, κ = 0.925). Main pancreatic duct diameters increased significantly after secretin stimulation: pancreatic head, 10.5% (mean); body, 12.5%; and tail, 7.7%. Pancreatic exocrine function evaluated according to assessment of duodenal filling was as follows: grade 0 (restricted function) in 0.7% of subjects by both readers, grade 1 (reduced function) in 4.8% of subjects by reader 1 and 4.5% of subjects by reader 2, grade 2 (low-grade reduced function) in 31.1% of subjects by reader 1 and 26.5% of subjects by reader 2, and grade 3 (physiologic function) in 63.4% of subjects by reader 1 and 68.3% of subjects by reader 2 (interrater agreement, κ = 0.838). The mean total excreted volume was 111.8 ± 49.8 (SD) mL, and the mean pancreatic flow output was 9.6 ± 4.2 mL/min. CONCLUSION: Secretin-stimulated MRCP moderately improves main pancreatic duct visualization and allows noninvasive quantification of pancreatic exocrine function with a negligible risk of side effects.
Authors: Robin Bülow; Peter Simon; Robert Thiel; Patrick Thamm; Philip Messner; Markus M Lerch; Julia Mayerle; Henry Völzke; Norbert Hosten; Jens-Peter Kühn Journal: Eur Radiol Date: 2014-08-15 Impact factor: 5.315
Authors: Cheryl E Gariepy; Melvin B Heyman; Mark E Lowe; John F Pohl; Steven L Werlin; Michael Wilschanski; Bradley Barth; Douglas S Fishman; Steven D Freedman; Matthew J Giefer; Tanja Gonska; Ryan Himes; Sohail Z Husain; Veronique D Morinville; Chee Y Ooi; Sarah J Schwarzenberg; David M Troendle; Elizabeth Yen; Aliye Uc Journal: J Pediatr Gastroenterol Nutr Date: 2017-01 Impact factor: 2.839
Authors: Brendan M McCleary; Andrew T Trout; Lin Fei; Qin Sun; Suraj D Serai; Jonathan R Dillman; Maisam Abu-El-Haija Journal: Pediatr Radiol Date: 2020-02-11
Authors: Chang-Il Kwon; Jae Hee Cho; Sung Hoon Choi; Kwang Hyun Ko; Temel Tirkes; Mark A Gromski; Glen A Lehman Journal: Korean J Intern Med Date: 2019-02-25 Impact factor: 2.884
Authors: Norbert Hosten; Robin Bülow; Henry Völzke; Martin Domin; Carsten Oliver Schmidt; Alexander Teumer; Till Ittermann; Matthias Nauck; Stephan Felix; Marcus Dörr; Marcello Ricardo Paulista Markus; Uwe Völker; Amro Daboul; Christian Schwahn; Birte Holtfreter; Torsten Mundt; Karl-Friedrich Krey; Stefan Kindler; Maria Mksoud; Stefanie Samietz; Reiner Biffar; Wolfgang Hoffmann; Thomas Kocher; Jean-Francois Chenot; Andreas Stahl; Frank Tost; Nele Friedrich; Stephanie Zylla; Anke Hannemann; Martin Lotze; Jens-Peter Kühn; Katrin Hegenscheid; Christian Rosenberg; Georgi Wassilew; Stefan Frenzel; Katharina Wittfeld; Hans J Grabe; Marie-Luise Kromrey Journal: Healthcare (Basel) Date: 2021-12-24